Md. Code, Health - General § 21-2C-16
This is the official text of Md. Code, Health - General § 21-2C-16, part of Maryland’s Code, Health - General — covers public health regulation.
Not legal advice. This page reproduces the official text of a government statute for reference only. Laws change, and how a statute applies depends on your specific facts. For advice about your situation, consult a licensed attorney in your state.
§21–2C–16.
Official statutory text
§21–2C–16. ** CONTINGENCY – IN EFFECT – CHAPTERS 610 AND 611 OF 2025 **
(a) (1) The Board, in consultation with the Stakeholder Council, shall determine whether, in addition to setting upper payment limits in accordance with § 21–2C–14 of this subtitle, it is in the best interest of the State for the Board to establish a process for setting upper payment limits for purchases and payor reimbursements of prescription drug products in the State that the Board determines have led or will lead to an affordability challenge.
(2) When making a determination under paragraph (1) of this subsection, the Board shall consider, if applicable:
(i) Contract and budget data provided to the Board that demonstrates savings to the State or local governments as a result of upper payment limits set in accordance with § 21–2C–14 of this subtitle;
(ii) Success of setting upper payment limits in other states; and
(iii) Expected savings from Medicare Maximum Fair Prices set by the Centers for Medicare and Medicaid Services.
(b) (1) If the Board makes an affirmative determination under subsection (a) of this section, the Board, in consultation with the Stakeholder Council, shall establish a process for setting upper payment limits for purchases and payor reimbursements of prescription drug products in the State that the Board determines have led or will lead to an affordability challenge.
(2) The process established under paragraph (1) of this subsection shall:
(i) To the extent appropriate, use the plan of action approved under § 21–2C–13(d) of this subtitle; and
(ii) Otherwise comply with the requirements for setting upper payment limits established under this subtitle.
(3) Before establishing an upper payment limit that applies to the Maryland Medical Assistance Program, the Board shall confer with the Maryland Medical Assistance Program to approve the application of the upper payment limit by assessing whether the proposed upper payment limit will:
(i) Conflict with the Medicaid Drug Rebates Program, the Covered Outpatient Drug Rule (CMS–2345–FC), or any other federal requirements as applicable; and
(ii) Require additional funding to be allocated to the Maryland Medical Assistance Program budget.
§21–2C–16. ** CONTINGENCY – NOT IN EFFECT – CHAPTERS 610 AND 611 OF 2025 **
(a) (1) The Board, in consultation with the Stakeholder Council, shall determine whether, in addition to setting upper payment limits in accordance with § 21–2C–14 of this subtitle, it is in the best interest of the State for the Board to establish a process for setting upper payment limits for purchases and payor reimbursements of prescription drug products in the State that the Board determines have led or will lead to an affordability challenge.
(2) When making a determination under paragraph (1) of this subsection, the Board shall consider, if applicable:
(i) Contract and budget data provided to the Board that demonstrates savings to the State or local governments as a result of upper payment limits set in accordance with § 21–2C–14 of this subtitle;
(ii) Success of setting upper payment limits in other states; and
(iii) Expected savings from Medicare Maximum Fair Prices set by the Centers for Medicare and Medicaid Services.
(b) (1) If the Board makes an affirmative determination under subsection (a) of this section, the Board, in consultation with the Stakeholder Council, shall establish a process for setting upper payment limits for purchases and payor reimbursements of prescription drug products in the State that the Board determines have led or will lead to an affordability challenge.
(2) The process established under paragraph (1) of this subsection shall:
ermination under subsection (a) of this section, the Board, in consultation with the Stakeholder Council, shall establish a process for setting upper payment limits for purchases and payor reimbursements of prescription drug products in the State that the Board determines have led or will lead to an affordability challenge.
(2) The process established under paragraph (1) of this subsection shall:
(i) To the extent appropriate, use the plan of action approved under § 21–2C–13(d) of this subtitle; and
(ii) Otherwise comply with the requirements for setting upper payment limits established under this subtitle.
(3) Before establishing an upper payment limit that applies to the Maryland Medical Assistance Program, the Board shall confer with the Maryland Medical Assistance Program to approve the application of the upper payment limit by assessing whether the proposed upper payment limit will:
(i) Conflict with the Medicaid Drug Rebates Program, the Covered Outpatient Drug Rule (CMS–2345–FC), or any other federal requirements as applicable; and
(ii) Require additional funding to be allocated to the Maryland Medical Assistance Program budget.
(c) (1) Subject to paragraph (2) of this subsection, if the Board establishes a process under subsection (b) of this section, the Board shall set upper payment limits for purchases and payor reimbursements of prescription drug products in the State in accordance with the process.
(2) This subsection does not apply with respect to:
(i) Payor reimbursements under Medicare Part C and D Plans;
(ii) Purchases under the federal 340B Drug Pricing Program; and
(iii) Purchases and payor reimbursements by federal agencies or federal programs that the State is preempted from regulating by federal law.
(a) (1) The Board, in consultation with the Stakeholder Council, shall determine whether, in addition to setting upper payment limits in accordance with § 21–2C–14 of this subtitle, it is in the best interest of the State for the Board to establish a process for setting upper payment limits for purchases and payor reimbursements of prescription drug products in the State that the Board determines have led or will lead to an affordability challenge.
(2) When making a determination under paragraph (1) of this subsection, the Board shall consider, if applicable:
(i) Contract and budget data provided to the Board that demonstrates savings to the State or local governments as a result of upper payment limits set in accordance with § 21–2C–14 of this subtitle;
(ii) Success of setting upper payment limits in other states; and
(iii) Expected savings from Medicare Maximum Fair Prices set by the Centers for Medicare and Medicaid Services.
(b) (1) If the Board makes an affirmative determination under subsection (a) of this section, the Board, in consultation with the Stakeholder Council, shall establish a process for setting upper payment limits for purchases and payor reimbursements of prescription drug products in the State that the Board determines have led or will lead to an affordability challenge.
(2) The process established under paragraph (1) of this subsection shall:
(i) To the extent appropriate, use the plan of action approved under § 21–2C–13(d) of this subtitle; and
(ii) Otherwise comply with the requirements for setting upper payment limits established under this subtitle.
(3) Before establishing an upper payment limit that applies to the Maryland Medical Assistance Program, the Board shall confer with the Maryland Medical Assistance Program to approve the application of the upper payment limit by assessing whether the proposed upper payment limit will:
(i) Conflict with the Medicaid Drug Rebates Program, the Covered Outpatient Drug Rule (CMS–2345–FC), or any other federal requirements as applicable; and
(ii) Require additional funding to be allocated to the Maryland Medical Assistance Program budget.
§21–2C–16. ** CONTINGENCY – NOT IN EFFECT – CHAPTERS 610 AND 611 OF 2025 **
(a) (1) The Board, in consultation with the Stakeholder Council, shall determine whether, in addition to setting upper payment limits in accordance with § 21–2C–14 of this subtitle, it is in the best interest of the State for the Board to establish a process for setting upper payment limits for purchases and payor reimbursements of prescription drug products in the State that the Board determines have led or will lead to an affordability challenge.
(2) When making a determination under paragraph (1) of this subsection, the Board shall consider, if applicable:
(i) Contract and budget data provided to the Board that demonstrates savings to the State or local governments as a result of upper payment limits set in accordance with § 21–2C–14 of this subtitle;
(ii) Success of setting upper payment limits in other states; and
(iii) Expected savings from Medicare Maximum Fair Prices set by the Centers for Medicare and Medicaid Services.
(b) (1) If the Board makes an affirmative determination under subsection (a) of this section, the Board, in consultation with the Stakeholder Council, shall establish a process for setting upper payment limits for purchases and payor reimbursements of prescription drug products in the State that the Board determines have led or will lead to an affordability challenge.
(2) The process established under paragraph (1) of this subsection shall:
ermination under subsection (a) of this section, the Board, in consultation with the Stakeholder Council, shall establish a process for setting upper payment limits for purchases and payor reimbursements of prescription drug products in the State that the Board determines have led or will lead to an affordability challenge.
(2) The process established under paragraph (1) of this subsection shall:
(i) To the extent appropriate, use the plan of action approved under § 21–2C–13(d) of this subtitle; and
(ii) Otherwise comply with the requirements for setting upper payment limits established under this subtitle.
(3) Before establishing an upper payment limit that applies to the Maryland Medical Assistance Program, the Board shall confer with the Maryland Medical Assistance Program to approve the application of the upper payment limit by assessing whether the proposed upper payment limit will:
(i) Conflict with the Medicaid Drug Rebates Program, the Covered Outpatient Drug Rule (CMS–2345–FC), or any other federal requirements as applicable; and
(ii) Require additional funding to be allocated to the Maryland Medical Assistance Program budget.
(c) (1) Subject to paragraph (2) of this subsection, if the Board establishes a process under subsection (b) of this section, the Board shall set upper payment limits for purchases and payor reimbursements of prescription drug products in the State in accordance with the process.
(2) This subsection does not apply with respect to:
(i) Payor reimbursements under Medicare Part C and D Plans;
(ii) Purchases under the federal 340B Drug Pricing Program; and
(iii) Purchases and payor reimbursements by federal agencies or federal programs that the State is preempted from regulating by federal law.
Status: in_force · Read it on the official government site
Need a lawyer in Maryland?
Find a Maryland lawyer
About this page: Statute text is reproduced from official government publishers via the
Open US Law dataset
(Vaquill AI, snapshot v2026.08, CC BY 4.0). Primary legislative text like this is public domain under the government-edicts doctrine
(Georgia v. Public.Resource.Org, 2020). We link every section back to its official source so you can verify it independently.